












httpChronic kidney disease and dialysis access in women
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Chronic kidney disease currently affects one in nine Americans and over 500,000 have progressed to failure requiring
kidney replacement therapy, with nearly 45% being women. Clinical Practice Guidelines have been developed in an effort
to synthesize the latest literature, particularly randomized controlled trials, to assist clinical decision making. Women have
different levels of kidney function than men at the same level of serum creatinine and may also lose kidney function over
time more slowly than men. Although the arteriovenous ﬁstulae have long been recognized as the preferred access for
hemodialysis, women are less likely to initiate dialysis with an arteriovenous ﬁstula in place. In addition, the female sex
is regarded as a risk factor for access failure as well for complications such as steal. This article reviews treatment of women
with chronic kidney disease, focusing on the difﬁculties they are perceived to have with dialysis access. (J Vasc Surg
2013;57:49S-53S.)Chronic kidney disease (CKD) currently affects one in
nine Americans and over 500,000 have progressed to
failure requiring kidney replacement therapy (KRT). Of
these, nearly 45% are women.1 Clinical Practice Guidelines
have been developed in an effort to synthesize the latest
literature, particularly randomized controlled trials, to assist
clinical decision making. Women have different levels of
kidney function than men at the same level of serum creat-
inine and may also lose kidney function over time more
slowly than men. Although the arteriovenous ﬁstulae
(AVF) have long been recognized as the preferred access
for hemodialysis, women are less likely to initiate dialysis
with an AVF in place. In addition, the female sex is
regarded as a risk factor for access failure as well for compli-
cations such as steal. This article reviews treatment of
women with CKD, focusing on the difﬁculties they are
perceived to have with dialysis access.
CKD IN WOMEN
Incidence and prevalence of CKD. Diabetes, conges-
tive heart failure, and CKD are interrelated chronic diseases.
The National Health and Nutrition Examination Survey
(NHANES) provides information on the increasing burden
of diabetes with a prevalence reaching 7.7% of the general
population in the years 2003-2006. The prevalence of
congestive heart failure has also increased to 2.5% during
this time period. Understanding the prevalence of CKD in
the population is more difﬁcult as renal function declines
with age, but approximately 10% to 15% of individuals are
estimated to have CKDbased on either low kidney function,the Mount Sinai Medical Center.
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://dx.doi.org/10.1016/j.jvs.2012.10.117deﬁned as an estimated glomerular ﬁltration rate (eGFR)
less than 60 mL/min/1.73m2, and/or persistent albumin-
uria/proteinuria.2 The Modiﬁcation of Diet in Renal
Disease (MDRD) Study equation is currently the most
commonly used to assess kidney function with eGFR. The
newer Chronic KidneyDisease Epidemiology Collaboration
(CKD-EPI) equation (Appendix, online only) is based on
the same four variables as the MDRD Study equation:
creatinine, age, sex, and race but has less bias and great
precision compared with the MDRD Study equation, using
the gold standard, measured GFR.3 Both of these equations
use female sex as a variable to account for the fact that men
have a higher level of kidney function at the same level of
serum creatinine, as a result of higher muscle mass and
creatinine generation on average in males. This is concep-
tually important to recognize because physicians who
refer for vascular access at a ﬁxed level of serum creatinine, 4
mg/dL for example, would be systematically referring
women at a lower level of kidney function or more advanced
disease.
Progression to end-stage renal disease (ESRD). Sex
may inﬂuence the progression of CKD, although the avail-
able literature is sometimes conﬂicting. Several studies
have shown that CKD progresses more slowly in women
than in men, a ﬁnding that may be attributed, at least in
part, to the effect of estrogen. Silbiger and Neustein have
found that men progress to end-stage renal failure more
rapidly than women when the underlying etiology is
polycystic kidney disease, membranous nephropathy, IgA
nephropathy, and chronic renal disease of unknown eti-
ology. In type 1 diabetesmellitus, menmay bemore likely to
exhibit signs of CKD, such as proteinuria.4-6 A similar
ﬁnding ofmore rapid progression inmales was seen in a large
cohort of patients in British Columbia referred to
a nephrologist for an eGFR of less than 30 mL/min/1.73
m2 who had at least three subsequent eGFR values and
4 months of follow-up over the 4-year study period. As
expected, 76% of the rapid progressors required KRT
compared with 27% slower progressors with a hazard ratio
for men for KRT of 1.489.7 Similar ﬁndings were seen in
a population-based study of men and women with stage 3
CKD in Norway.849S
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tigate sex differences but to test the effects of dietary
protein restriction and reduction of blood pressure on
the progression of renal disease, sufﬁcient numbers of
women were enrolled to allow this type of analysis. Female
participants had a lower incidence of glomerular diseases,
including hereditary nephritis and diabetic nephropathy,
than the men did. Older women had higher mean arterial
pressure, body weight, and body mass index in comparison
to younger women. No similar difference was seen in the
males. Renal disease progressed at a slower rate in women,
especially in the younger group. After controlling for
proteinuria, mean arterial pressure and HDL cholesterol,
sex differences were no longer signiﬁcant.9
The association of slower progression of CKD in the
female sex on the progression of kidney disease is not sup-
ported by all studies. Analysis of the ACE Inhibition in
Progressive Renal Disease Study Group database contain-
ing information on a large number of patients with nondi-
abetic renal disease showed that men did not progress more
quickly once characteristics such as age, race, mean arterial
pressure, and urinary protein were controlled. However,
most of the female patients in this database were older
and presumably postmenopausal. These ﬁndings may not
apply to younger women.10
Although renal disease may not progress as rapidly in
women as in men, CKD may be slightly more common in
women than inmen.11 A better understanding of what other
characteristics, besides sex, inﬂuence the likelihood of
progression will be important in planning for early access.
For example, in diabetic renal disease, the protective effect
of the female sex is less clear and the exact relationship
between sex hormones and renal function is uncertain.12,13
DIALYSIS ACCESS
Referral for permanent dialysis access. Current
National Kidney Foundation (NKF) Kidney Disease
Outcomes Quality Initiative (KDOQI) Clinical Practice
guidelines recommend patients with eGFR less than
30 mL/min/1.73 m2 should be educated on all KRT
options, including transplantation, to allow timely referral
for vascular access.14 How the anticipated progression to
end-stage renal failure affects the referral for access is
unknown, as more speciﬁc standards to determine who is
a candidate for permanent access have not yet been
established. A survey of American and Canadian nephrol-
ogists regarding their referral preferences demonstrated
great variability in the timing and criteria used. Advanced
age had the greatest impact on referrals especially in the
presence of extensive comorbidities and/or prior failed
access. Sex did not have an inﬂuence.15
Of course, this assumes patients detected with CKD are
being treated by a nephrologist. Healthy People 2010 (HP
2010) are national health objectives designed to identify the
most signiﬁcant preventable threats to health and establish
national goals to reduce these threats. CKD is one of the
28 focus areas. The goal of HP2010 Objective 4.3 is
to “increase the proportion of treated chronic kidney failurepatients receiving counseling on nutrition, treatment
choices and cardiovascular care 12 months before the start
of renal replacement therapy.” In 2008, however, less
than one-third of CKD patients received referrals to
nephrologists. In this regard, men and women were essen-
tially equal with 28.2% of males referred to nephrologists
compared with 28.6% of females. Referrals to dieticians
were very low for both groups, with men at a slightly higher
rate of 4.1% compared with only 3.7% for women. In
contrast, over 70% of CKD patients received information
about transplant with men at a slightly higher rate (72.9%)
than women (71.4%).16
Dialysis access placement. Using an autologous dial-
ysis access as opposed to an artiﬁcial conduit, most com-
monly expanded polytetraﬂuoroethelyene graft (ePTFE) or
a bovine carotid artery graft, is well supported in the litera-
ture and is the focus of the Fistula First Initiative. In 1997,
the Centers for Medicare and Medicaid Services sponsored
the AV Fistula First Breakthrough Initiative and National
Kidney Foundation Kidney Disease Outcomes Quality
Initiative Clinical Practice Guidelines were released. This
action was taken because AV ﬁstulas are superior to both
grafts and catheters in terms of patient morbidity and
mortality, patency, risk for infection, and other nonthrom-
botic complications.17 Originally, the goal was that at least
50% of access placed in new ESRD patients be AV ﬁstulas
and that 40% of prevalent patients receive dialysis treatment
via an AV ﬁstula.18 ANational Vascular Access Improvement
Initiative was created to help with the logistics of achieving
these measures and, by August 2005, the benchmark of 40%
prevalence was achieved. AV Fistula First Breakthrough
Initiative issued new guidelines, resetting the expectation of
ﬁstula creation to 66% by 2009.19 As of December 2010,
however, we are only at a 57.5% ﬁstula formation rate.20
Women in the prevalent group of ESRD patients
continue to fare worse in terms of desirable access. In
2007, only 41.3% of incident patients met this goal. Men
were more likely to use AVF in their ﬁrst year (47.5%)
compared with only 32.6% of women.21 Several studies
have conﬁrmed that female sex is one of the variables asso-
ciated with the lack of a ﬁstula at initiation of dialysis, in
addition to obesity and cause of ESRD among other
factors.22-25 A small study of 93 patients at a single center
in Canada found that rate of deterioration in kidney func-
tion and the presence of peripheral vascular disease were
associated with a lack of ﬁstula at initiation, but sex did
not play a role. This study was limited by a small sample
size to detect differences between men and women.26
Despite calls to reduce their use, catheters provide access
for 17% to 18% of prevalent patients in the United States
since 2003. Catheter use is more common in women than
in men; in 2007, the percentages were 22.9% in women
compared with 13.3% in men. Although ﬁstula use has
increased to 55.0% in 2007, women lag behind men in
this regard, as 64.2% of males have AVF but just over 40%
of females do so. Although the number of arteriovenous
grafts continues to fall, women are much more likely to
use a graft as access than men.27 Ethier et al published
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Outcomes and Practice Patterns Study (DOPPS), a prospec-
tive, observational study of hemodialysis practices and
patient outcomes at more than 300 hemodialysis units
from 12 countries. Across three phases of data collection,
patients were consistently less likely to use AVF if female.28
The Dialysis Outcomes and Practice Patterns Study from
2002 found that in Europe and the United States, the
adjusted OR for the probability of receiving an AVF in
females vs males is 0.40 (P < .0001).29
A commonly cited reason for women being less likely
than men to receive AVF is that women in general have
smaller vasculature. A retrospective review of preoperative
vascular mapping of 192 patients over a 2-year period did
not conﬁrm this belief. There was no signiﬁcant difference
in vein size between men and women at any of the 17 sites
studied, even when patients were subdivided by race and
presence or absence of diabetes. Arterial size was found to
be signiﬁcantly larger in men than women in three of the
12 different sites measured. These sites were all in the
distal forearm. Nevertheless, 62% of patients received AVF
with no signiﬁcant difference between the sexes. Percent-
ages of AVFs successfully used at the initiation of dialysis
were 72% in women and 78% in men (r ¼0.57).30 These
ﬁndings on preoperative mapping were similar to those re-
ported by Peterson, although his group found that female
gender was a factor in primary ﬁstula failure.31 Several
authors have concluded that, for women, AVF based on
the brachial artery rather than the radial are preferred, after
evaluating patency rates for various types of access.32-34 As
these were retrospective reviews, the reason for the disad-
vantaged patency rates at the wrist could not be determined.
COMPLICATIONS
Infection. Some of the more common vascular access
complications include infection, thrombosis, and steal
syndrome. Infection is the second most common complica-
tion after thrombosis. The European Dialysis and Trans-
plant Registry ranks infection second to cardiovascular
disease as a major cause of morbidity and mortality in
chronic hemodialysis patients.35 An ePTFE is associated
with up to a ﬁvefold increase in infection. A large prospective
cohort study from Canada found a 19.7% probability of
ePTFE graft infection compared with a 4.5% rate for
autologous AVF.36 Others report lower infection rates with
a single center noting only a 3.5% incidence. Risk factors for
infection include diabetes mellitus, insertion in the thigh,
history of multiple infections, number of surgical revisions,
immune compromised state, obesity, and old thrombosed
abandoned grafts.37 Female sex has not been shown to be
a risk factor for an increased rate in infection.
Access failure. The new revised Centers for Medicare
and Medicaid Services guidelines established a national
quality goal of 66% AVF prevalence by 2009. As of early
2011, prevalence of AVF has signiﬁcantly increased from
45.3% to over 55.5% in the United States (P < .001).38
The increasing demand for AVF creation highlights two
other complications: failure of maturation and thrombosis.Success of an AVF to provide adequate hemodialysis has
been negatively linked to the female sex.39 Vernaglione
et al looked at AVF survival in women and found that
female sex was an independent risk factor for AVF failure
(relative risk, 1.64; P ¼ .018) and that AVFs failed sooner
in women than in men with a 50% failure rate at a mean of
175 days for women and 700 days for men.40 Miller et al
also showed a similar decreased rate of ﬁstula adequacy in
women. He reported on 189 patients with a known ﬁstula
outcome. He found that 80 (42% of the total) were
adequate for dialysis, whereas 109 (58% of the total) were
inadequate to maintain a dialysis session. The reasons listed
for ﬁstula inadequacy include early thrombosis (22%),
technical failures (7%), and failure to mature (29%). He
found that the overall ﬁstula adequacy rate was about one-
third lower among women compared with men (P ¼ .001)
and that inferior outcome was noted for both forearm and
upper arm ﬁstulas.41 Similar to Caplin et al ﬁndings,30 he
did not ﬁnd signiﬁcance in vein size on preoperative
mapping between the sexes. Both did ﬁnd a signiﬁcant
difference in arterial size in the forearm radial arteries, and
Miller also found a signiﬁcantly smaller artery size in the
upper arm in women compared to men (P < .001). This at
ﬁrst was thought to be the reason for the great difference in
successful AVF between women and men. However, when
he compared the vessel diameter between inadequate and
adequate ﬁstulas in both men and women, Miller found no
correlation to the vessel size preoperatively. He also found
that salvage procedures were performed twice as often
for women compared with men (42% vs 23%; P ¼ .04)
and that of the four types of salvage procedures (percuta-
neous transluminal angioplasty, tributary ligation, super-
ﬁcialization, and surgical revision), superﬁcialization
accounted for 30% of the cases in women vs 8% in men
(P ¼ .04).41
Not all studies show the same disparity between
women and men for AVF survival. A group from Croatia
showed a median survival for of 38 months for AVF and
it was not affected by sex.42 Ehkut et al also showed no
difference in primary patency.43 These small studies do at
least provide hope that, at some point, women may beneﬁt
from the same rates of successful ﬁstula use typically ex-
pected in men.
A database review by Marcus et al analyzes the risk
factors for AVF failure in women and describes some clinical
strategies to help improve AVF utilization and success for
female patients. Preoperative ultrasound evaluation of the
upper extremity veins may be even more important in
women given the tendency for a greater amount of subcuta-
neous fat than seen in men, making assessment of the suit-
ability of the superﬁcial veins for AVF creation more difﬁcult
in women if the clinician relies on physical examination
alone. Other suggestions include pre- and postoperative
arm exercise to increase vessel diameter, use of regional
blocks for anesthesia, routine intra- and postoperative moni-
toring, and early intervention as indicted by the ﬁndings and
control of secondary hyperparathyroidism. These strategies
may not necessarily have been studied particularly in women
JOURNAL OF VASCULAR SURGERY
52S Pounds and Teodorescu April Supplement 2013but have been found to provide the best circumstances to
achieve an adequately functioning ﬁstula. The authors
suggest that a greater effort to achieve success may be neces-
sary to overcome that negative effects that concerns
regarding higher access failure rates in women may have.44
Steal. Dialysis-associated steal syndrome is a relatively
rare but quite serious complication. It is the result of an
altered hemodynamic ﬂow with tissue ischemia distal to
the access. The clinical incidence of symptomatic steal is
0.25% to 1.8% for forearm ﬁstulas and higher for upper
arm autologous or prosthetic grafts (range, 3% to 7%).45
The accepted risk factors include a history of diabetes,
multiple previous access placements, older age, and a history
of signiﬁcant peripheral arterial disease, which could also
affect the upper extremity.46 Some authors consider being
female a risk factor47 and others do not. Goff et al published
a series examining 1800 patients to determine whether
intraoperative noninvasive testing could reliably predict
whether steal syndrome would occur. He found that
a digital-brachial index less than 0.6 identiﬁes a patient at
risk for steal. He had more women in both arms of his study
with steal, but it did not reach statistical signiﬁcance.48
Huber et al published midterm results from his series of
distal revascularization and interval ligation procedures. He
had 61 patients with a 62% female distribution, but this
again was not statistically signiﬁcant.49 As it has been shown
that females do have smaller radial and brachial arteries,
a high-ﬂow ﬁstula or graft (>750 mL/min) could exceed
the capacity of the feeding arterial system even in the
absence of distal obstruction.45-47 Regardless if female sex is
a risk factor, prompt diagnosis is essential and treatment
should be initiated quickly. The details for treatment
options are outside the scope of this article but easily found
in any text book.47
Ischemic monomelic neuropathy. Ischemic mono-
melic neuropathy is a rare complication of access proce-
dures marked by symptoms of polyneuropathy in the
absence of clinically apparent arterial insufﬁciency. Diag-
nosis may be difﬁcult, as patients are likely to have diabetes
mellitus and neuropathy as a consequence of long-standing
metabolic disease. Early recognition is imperative, as the
best treatment is prompt ligation of the access or other
surgery to improve circulation to the hand as would be
done to correct steal. Failure to do so may result in loss of
function with development of a claw hand and disabling
pain. Like steal, female sex may be a risk factor for the
development of this complication.50-54SUMMARY
The incidence and prevalence of CKD in the United
States is increasing as the population ages. Female sex has
been found to be associated with the presence of renal
disease in multivariate analysis of NHANES data. Sex
may also be an important factor inﬂuencing the progression
of nondiabetic CKD with a slower rate seen in women.
This suggests that either the female sex is protective or
that the male sex is a risk factor for the development andprogression of CKD. This effect is not as clear in diabetic
patients.
Although women with CKD are referred to nephrolo-
gists at the same rate as men, females are much less likely to
initiate dialysis with an AVF. Although it is commonly
believed that women’s smaller vessels account for this
difference, studies have not conﬁrmed this belief. Why
women suffer from higher rates of access complications,
including failure to mature, steal, and ischemic monomelic
neuropathy is not well understood. Further investigation of
the problems women with CKD face in the creation and
maintenance of their dialysis access is necessary to increase
the prevalence of AVF in this group.
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APPENDIX (online only). The CKD-EPI
creatinine equation
GFR ¼ 141minðScr=k; 1ÞamaxðScr=k; 1Þ1:209
 0:993Age  1:018 ½if female  1:159 ½if black
where
k ¼ 0:7 if female
k ¼ 0:9 if male
a ¼ 0:329 if female
a ¼ 0:411 if male
min ¼ the minimum of Scr=k or 1
max ¼ the maximum of Scr=k or 1
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